Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2016 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. Hirschfield GM, et al. N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21. N Engl J Med. 2024. PMID: 38381664 Clinical Trial.
[Low mean cell hemoglobin is a reliable marker for iron deficiency screening].
Kellner SV, Kellner Á, Haragh A, Dombi P, Karádi É, Rajnics P, Kollár B, Alizadeh H, Ghosh M, Liposits A, Moizs M, Egyed M. Kellner SV, et al. Among authors: haragh a. Orv Hetil. 2016 Jan 3;157(1):35-8. doi: 10.1556/650.2016.30328. Orv Hetil. 2016. PMID: 26708685 Hungarian.
[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A, Pár G, Tornai I, Szalay F, Várszegi D, Fráter E, Papp M, Lengyel G, Fehér J, Varga M, Gervain J, Schuller J, Nemes Z, Péterfi Z, Tusnádi A, Hunyady B, Haragh A, Szinku Z, Pálinkás L, Berki T, Vincze A, Kisfali P, Melegh B. Pár A, et al. Among authors: haragh a. Orv Hetil. 2013 Aug 11;154(32):1261-8. doi: 10.1556/OH.2013.29680. Orv Hetil. 2013. PMID: 23916907 Hungarian.
IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Pár A, Pár G, Tornai I, Szalay F, Várszegi D, Fráter E, Papp M, Lengyel G, Fehér J, Varga M, Gervain J, Schuller J, Nemes Z, Péterfi Z, Tusnádi A, Hunyady B, Haragh A, Szinku Z, Vincze A, Szereday L, Kisfali P, Melegh B. Pár A, et al. Among authors: haragh a. BMC Res Notes. 2014 Jan 8;7:12. doi: 10.1186/1756-0500-7-12. BMC Res Notes. 2014. PMID: 24398031 Free PMC article.
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
Maasoumy B, Hunyady B, Calvaruso V, Makara M, Vermehren J, Haragh A, Susser S, Bremer B, Cloherty G, Manns MP, Craxì A, Wedemeyer H, Sarrazin C. Maasoumy B, et al. Among authors: haragh a. PLoS One. 2014 Nov 12;9(11):e110857. doi: 10.1371/journal.pone.0110857. eCollection 2014. PLoS One. 2014. PMID: 25389779 Free PMC article.
[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B, Abonyi M, Csefkó K, Gervain J, Haragh A, Horváth G, Jancsik V, Makkai E, Müller Z, Ribiczey P, Sipos B, Szabó O, Szalay F, Szentgyörgyi L, Tornai I, Újhelyi E, Varga M, Weisz G, Makara M. Hunyady B, et al. Among authors: haragh a. Orv Hetil. 2016 Aug;157(34):1366-74. doi: 10.1556/650.2016.30538. Orv Hetil. 2016. PMID: 27546804 Hungarian.